Trials / Completed

CompletedNCT00323102

A Study Comparing Two Magnetic Resonance Imaging (MRI) Contrast Agents in MRI of the Brain

Phase IV, Double-Blind, Multi-Center, Randomized, Cross-Over Study to Compare 0.10 Mmol/kg of MultiHance With 0.10 Omniscan in Magnetic Resonance Imaging (MRI) of the Brain

Status: Completed
Phase: Phase 4
Study type: Interventional
Enrollment: 114 (planned)

Sponsor: Bracco Diagnostics, Inc · Industry
Sex: All
Age: 18 Years
Healthy volunteers: Not accepted

Summary

This study aims at a direct comparison between Multihance and a validated comparator like Omniscan in a cross-over individual design in patients with brain tumors to confirm the superior overall diagnostic performance of MuliHance for this indication

Conditions

Brain Pathology

Interventions

Type	Name	Description
DRUG	Multihance

Timeline

Start date: 2006-05-01
Completion: 2007-03-01
First posted: 2006-05-09
Last updated: 2008-01-23

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00323102. Inclusion in this directory is not an endorsement.